Kronos Bio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
entospletinib (GS-9973) / Kronos Bio
2021-000761-33: Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormality

Not yet recruiting
3
180
Europe, RoW
Entospletinib, ENTO, Film-coated tablet, ARA-cell® 1000 mg solution for infusion50 mg/ml solution for infusion, Idarubicin Hikma 1 mg/mL solution for injection, Daunorubicin 20mg Powder for I.V. Injection
Kronos Bio, Inc., Kronos Bio Inc., Kronos Bio, Inc.
Acute Myeloid Leukemia, Acute Myeloid Leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
AGILITY, NCT05020665 / 2021-000761-33: Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

Terminated
3
15
Europe, Canada, US, RoW
Entospletinib, ENTO, GS-9973, Placebo, Cytarabine, Anthracycline
Kronos Bio, Kronos Bio, Inc.
Nucleophosmin 1-mutated Acute Myeloid Leukemia
03/23
03/23
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
NCT02457598: Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Terminated
1
203
Europe, US
Tirabrutinib, ONO/GS-4059, Idelalisib, Zydelig®, GS-1101, CAL-101, Entospletinib, GS-9973, Obinutuzumab
Gilead Sciences
B-cell Malignancies
09/24
09/24
lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Un estudio para evaluar Lanraplenib (LANRA) en combinación con Gilteritinib en participantes con leucemia mieloide aguda (LMA) en recidiva o resistente al tratamiento con mutaciones del gen FLT3

Not yet recruiting
1/2
55
Europe
Lanraplenib, Xospata, LANRA, Film-coated tablet, Xospata
Kronos Bio, Inc., Kronos Bio, Inc.
Acute Myeloid Leukemia Leucemia Mieloide Aguda, Acute Myeloid Leukemia Leucemia Mieloide Aguda, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
KB-LANRA- 1001, NCT05028751 / 2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated
1/2
24
Europe, US
Lanraplenib, LANRA, Gilteritinib, XOSPATA®
Kronos Bio, Kronos Bio, Inc.
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
04/24
04/24
ACTRN12616001548426: Evaluate the Pharmacokinetics of GS-9876 in Subjects with Impaired Renal Function

Recruiting
1
60
 
Gilead Sciences, Inc, Gilead Sciences, Inc
Inflammatory Diseases
 
 
istisociclib (KB-0742) / Kronos Bio
KB-0742-1001, NCT04718675: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Active, not recruiting
1/2
280
Europe, US
KB-0742
Kronos Bio
Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC, Platinum Resistant High Grade Serous Ovarian Cancer
12/25
12/25
Undisclosed AR TRN modulator / Kronos Bio
No trials found
Undisclosed transcription factor modulator / Roche, Kronos Bio
No trials found

Download Options